Abstract Targeted monoclonal antibodies (mAb) can be used therapeutically for tumors with identifiable antigens such as disialoganglioside GD2, expressed on neuroblastoma and melanoma tumors. Anti-GD2 mAbs (aGD2) can provide clinical benefit in patients with neuroblastoma. An important mechanism of mAb therapy is antibody-dependent cellular cytotoxicity (ADCC). Combinatorial therapeutic strategies can dramatically increase the anti-tumor response elicited by mAbs. We combined a novel aGD2 mAb, hu14.18K322A, with an immunostimulatory regimen of agonist CD40 mAb and class B CpG-ODN 1826 (CpG). Combination immunotherapy was more effective than the single therapeutic components in a syngeneic model of GD2-expressing B16 melanoma with minimal tumor burden. NK cell depletion in B6 mice showed that NK cells were required for the anti-tumor effect; however, antitumor responses were also observed in tumor-bearing SCID/beige mice. Thus, NK cell cytotoxicity did not appear to be essential. Peritoneal macrophages from anti-CD40 ? CpG-treated mice inhibited tumor cells in vitro in an hu14.18K322A antibody-dependent manner. These data highlight the importance of myeloid cells as potential effectors in immunotherapy regimens utilizing tumor-specific mAb and suggest that further studies are needed to investigate the therapeutic potential of activated myeloid cells and their interaction with NK cells.
Introduction
The most common immunotherapy for the treatment of cancer is monoclonal antibody (mAb) therapy. The anti-tumor effects of tumor-targeted mAbs generally occur through the activation of complement and/or antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent phagocytosis (ADCP) [1] . To maximize anti-tumor responses elicited by mAbs, much research has focused on immune activation alongside mAb administration. We report here on a combinatorial approach, with a unique mAb, hu14.18K322A, combined with anti-CD40 mAb (aCD40) and CpG, both potent stimuli of innate immune cells.
Hu14.18K322A is a humanized mAb that targets ganglioside D2 (GD2), a glycosphingolipid overexpressed by tumors of neuroectodermal origin, such as melanoma and neuroblastoma [2, 3] . Hu14.18K322A was specifically designed to minimize toxicities associated with anti-GD2 (aGD2) therapy. Due to limited expression of GD2 on healthy peripheral nervous tissue, the major dose-limiting toxicity associated with anti-GD2 therapy is allodynia and is dependent on complement activation [4] . One unique property of hu14.18K322A is a targeted mutation at amino acid 322 that replaces a lysine with an alanine. This specific mutation reduces antibody-mediated complement activation. Additionally, hu14.18K322A is produced in the rat hybridoma cell line YB2/0 that has low fucosyltransferase activity. Monoclonal antibodies with such altered side chains on the Fc portion are more potent inducers of ADCC [5, 6] . Combined, these unique features of hu14.18K322A are designed to reduce complement-related toxicities while maximizing effector responses by cells mediating ADCC.
Previous reports from our laboratory have used aCD40 either alone, or in combination with a class B CpG nucleotide in several tumor therapy models [7, 8] . aCD40 is a member of the TNF receptor superfamily and is found on many cells such as myeloid cells, endothelial cells, and platelets, among other cells. Agonist antibodies to CD40 (aCD40) initiate potent activation of cells expressing CD40, including dendritic cells and macrophages. CpG 1826 is a class B CpG-ODN that is recognized by TLR9. aCD40 ? CPG immunotherapy produces anti-tumor responses through the activation of innate immune effector cells such as NK cells and macrophages [9, 10] . Since many of the effector cell populations activated by aCD40 ? CpG are capable of mediating ADCC or ADCP, we tested the ability of aCD40 ? CpG to augment tumor-targeted mAb responses.
The studies presented in this report sought to maximize the anti-tumor effect of hu14.18K322A in a model of murine melanoma by co-administration of a CD40 agonist and TLR9 stimulus, CpG. In a model of minimal disease, we found a significant increase in the anti-tumor activity of hu14.18K322A when it was combined with aCD40 ? CpG. Therapeutic efficacy was independent of T cells and rechallenge studies indicated that immunological memory was not induced. We found a potential role for both NK cells and macrophages in the hu14.18K322A-mediated response. Overall, our data presented here demonstrated a clear enhancement of hu14.18K322A-dependent anti-tumor activity when mAb is combined with activation of innate effector cells using aCD40 ? CpG.
Materials and methods

Mice and tumor cell lines
Six-to ten-week-old C57BL/6 or SCID/beige mice (Taconic Farms) were housed and cared for in accordance with the Guide for Care and Use of Laboratory Animals and under an animal protocol approved by the animal care and use committee. B78D14 tumor cells are a B16F10 melanoma derivative cell line transfected with the gene coding b-1,4-N-acetylgalactosaminyltransferase resulting in the constitutive expression of GD2 on the cell surface [11] . Cells were grown in RPMI 1640 complete cell culture medium supplemented with 10 % heat-inactivated FCS (Sigma-Aldrich), 2 mM L-glutamine, 100 U/mL penicillin, and streptomycin at 37°C and 5 % CO 2 . Cells were cultured two passages prior to injection with 400 lg/mL Geneticin Neomycin and 50 lg/mL Hygromycin B for selection of cells expressing GD2. C57BL/6 mice were injected subcutaneously on the left abdomen with the indicated tumor cell number in 0.1 mL. Subcutaneous tumor growth was measured at indicated days after tumor implantation, and tumor volume was calculated using the formula [volume mm 3 = (length) 9 (width 2 ) 9 (0.52)]. ) is a genetically engineered form of the hu14.18 humanized anti-GD2 monoclonal antibody that has been mutated to prevent complement activation and grown in Y2 cells to limit fucosylation and enhance ADCC [4] . Hu14.18K322A was administered intravenously (25 lg/dose in 0.2 mL) for five consecutive days, beginning the day after the first aCD40 injection. For depletion studies, 0.1 mg aNK1.1 mAb, clone PK136 (ATCC), was injected i.p. in 0.2 mL starting two days prior to the first dose of aCD40 and repeated every 3 days for the first week of therapy while hu14.18K322A mAb was administered.
In vitro assay of macrophage activity Peritoneal exudate was collected by peritoneal lavage one day after one round of aCD40 ? CpG. Peritoneal exudate cells (PEC) were added to a 96-well round bottom plate in 0.1 mL of cell suspension at 10 6 cells/mL and serially diluted in the plate. Cells were then incubated for 1.5-2 h to allow for plastic adherence of macrophages, after which time non-adherent cells were removed by gently pipetting. 10 4 tumor cells were added per well with 10 lg/mL of hu14.18K322A. The assay was incubated overnight at 37°C and 5 % CO 2 . After overnight incubation, 1 lCi of 3 H-thymidine was added per well and incubated an additional 6-10 h. Total cells were harvested from the wells and onto a fiberglass filter using a Packard cell harvester, and relative beta counts were determined using a Packard Matrix 9600 direct beta counter (Packard instruments). Conditions were assayed in triplicate with 2-4 mice per experiment. The average count of each condition was graphed as a single point, and the averages of individual mice were graphed as replicates.
Depletion of macrophages in vivo
For some studies, phagocytic cells were depleted in vivo by injection of clodronate liposomes as previously described [12] . Clodronate was a gift from Roche Diagnostics GmbH, Mannheim, Germany.
Flow cytometry
To test for hu14.18K322A-labeling of B78D14 tumor cells, 1 lg of hu14.18K322A mAb used in therapeutic studies was incubated with 10 5 tumor cells at 4°C for 30 min, excess was washed off, and 1 lg of polyclonal PE-anti-human IgG (eBioscience, San Diego, CA) was secondarily used to detect bound hu14.18K322A. To determine macrophage loss after plate adherence, all of the cells that were removed from the plate or 10 5 PEC not adhered to plastic were labeled with 0.5 lg of each antibody, PE-Cy5 aF4/80 (clone BMB, eBioscience, San Diego CA) and Pacific Blue-aCD11b (Clone M1/ 70, Biolegend, San Diego, CA) for 30 min at 4°C. All flow cytometry was acquired on a BD LSRII (BD, San Jose, CA) and analyzed using FlowJo software (Treestar, Ashland, OR).
Statistics
Kaplan-Meier survival curves were generated and analyzed in Prism graphical software (Graphpad, La Jolla, CA); differences in survival were determined by applying a log-rank test. Tumor growth data were analyzed using a two-way ANOVA, and differences in F4/80 ? cells in the peritoneal fluid pre-and post-plastic adherence were determined by applying Student's t test. Data are presented as mean ± SD and considered significantly different when P values are below 0.05.
Results aCD40 ? CpG priming followed by hu14.18K322A can cure melanoma-bearing mice in a minimal disease setting Our initial hypothesis was that the priming of innate immune effector cells with aCD40 ? CpG would increase the anti-tumor effect of hu14.18K322A. Previous reports from our laboratory have shown that aCD40 ? CpG immunotherapy activates both NK cells and macrophages [8] [9] [10] . Furthermore, both NK cells and macrophages are effector cells capable of mediating ADCC against antibody-coated tumor cells [13] [14] [15] [16] . To address this hypothesis, we used B78D14, a B16F10-melanoma derived cell line that expresses GD2 and is therefore recognized by hu14.18K322A (Fig. 1a) .
To evaluate a combinatorial effect of aCD40 ? CpG and hu14.18K322A, we treated C57BL/6 mice bearing subcutaneous B78D14 tumors with combination immunotherapy or with each therapeutic component, that is, hu14.18K322A alone or aCD40 ? CpG. In some experiments, combination therapy started at different times after tumor injection; however, once therapy was initiated, a standard timing regimen was followed (Fig. 1b) . For our initial experiments, we began treatment of mice early, before mice had palpable tumors, 5 days after injection of tumor cells, and evaluated therapeutic efficacy by monitoring subcutaneous tumor growth and overall survival. Tumors in mice treated with combination immunotherapy, consisting of anti-CD40 ? CpG and hu14.18K322A, grew considerably slower than tumors in mice that were treated with either component of the regimen (Fig. 1c) . Many mice that received combination immunotherapy did not develop detectable tumors, leading to a significant increase in overall survival (Fig. 1d) . These results indicate that anti-CD40 ? CpG co-administration enhances the anti-tumor effectiveness of tumor-targeted mAb, hu14.18K322A, in a setting of minimal disease burden.
Because we observed complete and prolonged antitumor responses in mice with very small (non-palpable) tumors, we evaluated efficacy of combination immunotherapy against larger, more established tumors. We implanted mice with two initial doses of tumor cells, 0.5 9 10 6 and 2 9 10 6 , and started therapy at 3 different time points, day 5, 18, or 28 after tumor implantation (Fig. 2a) . The results of these studies indicated that tumor burden in this model affects the level of response to this form of combination immunotherapy. When mice were implanted with a smaller number of tumor cells, tumor an earlier therapy start was associated with better tumor inhibition and prolonged survival (Fig. 2b, c) . When mice were implanted with a larger number of tumor cells, only the earliest treatment regimen provided any detectible antitumor effect (Fig. 2d, e) . These data indicate that this combination immunotherapy in this model has maximum efficacy in situations of minimal disease.
To address a potential role of immunological memory in mice surviving long-term, we compared tumor growth in mice rendered tumor-free by this combined immunotherapy regimen and in aged matched control mice. Long-term tumor-free mice were defined as mice that had been challenged with tumor and received combined immunotherapy (as in Figs. 1 and 2 ) and survived with undetectable tumor for at least 100 days after the last tumor-bearing mouse had been euthanized. We did not observe a difference in tumor growth between long-term tumor-free mice and aged matched controls challenged with tumor for the first time (Fig. 2f) . From these experiments, we concluded that combination immunotherapy was not inducing detectible immunological memory; this suggested that the anti-tumor effect was likely being mediated by innate immune effector cells.
Anti-tumor effect of a combination of anti-CD40 ? CpG and hu14.18K322A in SCID/Beige mice To test whether T and B cell adaptive immune responses as well as NK cell-mediated ADCC are needed for this in vivo immunotherapeutic effect, we treated B78-bearing SCID/ beige mice; these mice are deficient in T and B cells and have a lysosomal mutation that impairs the cytolytic function of their NK cells [17, 18] . Most mature NK cells constitutively express Fc receptors (FcRs) and are powerful mediators of ADCC against antibody-opsonized targets [19] , but NK cells of SCID/beige mice are unable to 6 B78D14 tumor cells on day 0, and therapy was initiated 5 days after tumor cell implantation. Tumor cell growth (c) and overall survival (d) were followed after cessation of immunotherapy (and plotted based on the days after tumor implantation). Tumor growth and survival analyses consist of 6-8 mice per group and are representative of at least three independent experiments. * P \ 0.05 indicates a significant difference between the combination therapy (aCD40 ? CpG ? hu14.18K322A) group and all other groups on days 56 and 65 in (c), and for the comparison of the combination group survival curve to the other 3 in (d). In (d), the survival curves of the 3 groups other than the combination group are all superimposed on one another. Statistical analyses were completed using a two-way ANOVA (tumor growth), or a log-rank test (survival) mediate ADCC. Previous studies from our laboratory have shown anti-tumor effects in vivo from aCD40 ? CpG in SCID/beige mice bearing B16F10 melanoma tumors; depletion studies suggest that at least some component of this anti-tumor effect results from macrophage-mediated tumor destruction [7] . We implanted SCID/beige mice with 0.5 9 10 6 B78D14 melanoma tumor cells and followed tumor growth after treatment with combination immunotherapy or with either therapeutic component. Similar to our observations in normal C57BL/6 mice (Fig. 1c) , tumor growth was significantly slowed in SCID/beige mice when they were treated with combination immunotherapy (Fig. 3a) . Unlike wild-type (WT) C57BL/6 mice, we saw only a small separation between the anti-tumor activity of aCD40 ? CpG alone and the combination immunotherapy (Fig. 3a) . The greater difference in the tumor growth inhibition by the combined therapy (vs. aCD40 ? CpG alone) in the WT mice (Fig. 2b ) than in SCID/beige mice ( Fig. 3a) likely represents the partial contribution of NK cell-mediated lysis in WT mice in our therapy model. While aCD40 ? CpG-treated mice had slower initial tumor growth than control mice (Fig. 3a) , all of these mice developed tumor and their survival time was not increased compared to control mice (Fig. 3b) . However, some SCID/ beige mice treated with combination immunotherapy remained tumor-free and this translated into a significant increase in their survival time (Fig. 3b) . These data suggest that combination mAb-based immunotherapy retains some anti-tumor function in the absence of T cells, B cells, and NK cell-mediated lysis.
To further dissect the role of NK cells in the functional efficacy of combination immunotherapy, we depleted NK cells from tumor-bearing B57BL/6 mice with anti-NK1.1 mAb and treated them with combination immunotherapy (Fig. 4a) . Interestingly, while earlier studies suggested that mechanisms other than NK cell-mediated lysis could play a role in the anti-tumor responses, depletion studies suggested that the presence of NK cells was necessary. Depletion of NK cells with aNK1.1 mAb prior to and during combination immunotherapy abolished the antitumor effect (Fig. 4a, b) . Anti-tumor efficacy was also abrogated in mice depleted of phagocytic cells with clodronate-containing liposomes [12] ; however, since mice treated with control PBS-containing liposomes showed a slight but significant reduction in therapeutic benefit, these data were inconclusive (data not shown).
Activation of myeloid cells after anti-CD40 ? CpG in vivo
After observing anti-tumor activity in the absence of NK cell-mediated lysis, we used an in vitro system to evaluate the role of macrophages against hu14.18K322A-opsonized tumor cells. Macrophages and other myeloid cells are capable effectors against mAb-opsonized tumor cells [20] [21] [22] [23] . Furthermore, aCD40 ? CpG can activate macrophages in vivo to have tumoricidal activity [7] . However, we did not observe an increase in the expression level of Fc receptors CD16 or CD32 on peritoneal macrophages from aCD40 ? CpG treated mice (data not shown). We used plastic adherence to isolate macrophages, then co-cultured the adherent macrophages with tumor cells overnight (Fig. 5a ). Flow cytometric analysis of the cell suspension before and after plastic adherence suggested that the vast majority of the macrophages in the PEC population were retained by adherence on the plate (Fig. 5b-d) .
To test macrophage activity, we used macrophages from control or aCD40 ? CpG primed mice in a co-culture assay against tumor cells ± hu14.18K322A (Fig. 6a) . With this system, we observed potent anti-tumor activity by aCD40 ? CpG primed macrophages in an antibodydependent manner. These observations were consistent using peritoneal cells from normal C57BL/6 mice ( Fig. 6b) , CB.17 SCID mice (Fig. 6c) and SCID/beige mice (Fig. 6d) . Slight but significant increases in tumor cell lysis were observed in an 18-hr 51Cr-release assay, suggesting that adherent peritoneal cells from aCD40 ? CpG primed mice had increased cytotoxic capabilities (data not shown). These data suggest that aCD40 ? CpG primed macrophages can inhibit tumor cell proliferation in an antibody-dependent manner and may participate in the combinatorial anti-tumor effect of anti-CD40 ? CpG and hu14.18K322A in vivo.
Discussion
In this manuscript, we showed that the anti-tumor effectiveness of hu14.18K322A in vivo is enhanced by aCD40 ? CpG therapy. The benefit of combining hu14.18K322A with aCD40 ? CpG was particularly apparent in mice with small tumors. Notably, therapeutic efficacy depended more on tumor amount than time of establishment (Fig. 2) , indicating that this regimen may be effective in minimal residual disease. Combined therapy (with hu14.18K322A added to aCD40 ? CpG) was effective at eradicating small tumors and led to long-term survival in some animals; this was not seen in the experiments when mice received only hu14.18K322A or only aCD40 ? CpG. Long-term survival occurred in immunocompetent mice without inducing immunological memory and also could be induced by combined therapy in mice lacking T cells.
Secondary induction of adaptive immunity after monoclonal antibody-based therapy has been observed in various tumor models [24] [25] [26] , but the mechanism and the dominant effector cell population depends on the tumor type. Recently, Abes et al. observed the induction of a persistent, T cell-dependent, anti-tumor response elicited by aCD20 mAb, CAT-13 [24] . However, T cell involvement is likely tumor dependent as our group has previously shown that immunocytokine therapy with anti-EpCAM-IL-2 can induce a T cell response against tumor with high MHC class I expression, but not against low MHC class I variants of the same tumor [27] . In the latter case with poor MHC expression, NK cells are the dominant effector cell that responds to immunocytokine, and persistent T cell immunity is not achieved [27] . In this manuscript, we are using B78D14 tumor cells, a subclone of B16-F10. B16-F10 is well documented to have low expression of MHC class I, which may be one reason we did not observe a T cell response in this model.
We investigated the potential role of NK cells and macrophages, as both are capable of mediating ADCC. We have previously reported that aCD40 can activate both NK cells and macrophages in tumor-bearing mice [10, 28] . Our data presented here indicate that NK cells are required for therapeutic efficacy in vivo (Fig. 4b) ; however, studies using SCID/beige mice suggested that lytic function of NK cells might not be a requirement (Fig. 3) in vivo. Recently, a model of allogeneic cell rejection was used to demonstrate that macrophage effector functions cannot be well deciphered in vivo unless NK cell function is impaired [29] . Previous studies from our laboratory [9] and others [30] have shown that interferon-c (IFNc) is required for macrophage activation in certain mouse models of tumor immunotherapy. NK cells are the primary source of IFNc after in vivo administration of CpG ? antibody-coated tumor cells [31] . Furthermore, co-administration of interleukin-12 alongside Trastuzumab therapy produces greater anti-tumor responses and is dependent on NK cell production of IFNc [32] . Both anti-CD40 [10] and CpG 1826 [33] promote secretion of IFNc when administered independently. Therefore, while it may be difficult to separate the independent contributions of macrophages and NK cells in vivo, NK cell production of IFNc in SCID/ beige mice that would be absent in NK cell depleted mice may explain the difference in results between these two settings (Figs. 3, 4) .
Enhancement of ADCC by CpG activation of effector cells was initially shown in the late 1990s in a mouse model of B cell lymphoma [34] . Much of this was assumed to be the direct activation NK cells, which has been described for both human and mouse NK cells [31, 35] . Subsequently, two classes of CpG-containing oligonucleotides, class-A and B, were described to activate different effector populations involved in ADCC [36] . In vivo depletion studies have been used to show that while CpG-A-enhanced ADCC requires only NK cells, CpG-Benhanced ADCC is mediated by both NK cell and granulocytes [36] . CpG therapy was combined with rituximab in a phase II trial in patients with follicular lymphoma, in which responses were similar to those previously reported for rituximab alone [37] . However, the patients in the combination trial had all undergone prior rituximab treatment, and therefore, comparison of the two reported response rates may be unfair [37] . The route of CpG administration may affect its ability to enhance ADCC. Intratumoral CpG rather than systemic CpG was shown to be better at increasing the anti-tumor activity of an aCD20 antibody [38] . In our model system, we have observed that priming with aCD40 increases the expression of TLR9 by macrophages peaking at 3 days after aCD40. Therefore, Fig. 5 In vitro Assay of Macrophage Anti-tumor Activity. a Assay schematic of in vitro system used to evaluate anti-tumor activity by macrophages. b Representative flow cytometry dot plots of peritoneal exudate before the plastic adherence and the cells that were removed following the plastic adherence step of the in vitro assay; macrophages were defined as CD11b ? F4/ 80 ?. c Bar graphs showing that macrophages were left on the plate by comparing the percentage of macrophages in the peritoneal fluid pre-and post-plastic adherence. Bar graphs are the combination of 4 mice per group and significant differences were determined by a student's t test we used this information to devise our treatment regimen. We believe that in addition to activating macrophages and other cells of the innate immune system, aCD40 is sensitizing cells to TLR9 activation resulting in an augmented response to CpG.
Studies depleting macrophages in vivo with clodronate liposomes [12] were inconclusive in our hands; while the antitumor effect of the combined therapy was substantially reduced by treatment with the clodronate liposomes, treatment of tumor-bearing mice with control, PBS-containing, liposomes also slightly but significantly reduced the antitumor effect of therapy. However, a recent publication by Tsai and colleagues suggested that phagocytosis of gold particles larger than 4 nm in size reduced the cellular response to TLR9 [39] . Tsai et al. [39] concluded that the effect was due to a gold-specific interference of high mobility groupbox 1 that regulates TLR9 signaling. As they did not compare gold nanoparticles to a non-gold control, they could not conclusively say if the inhibition of TLR9 responses was restricted to gold particles, or possibly a function of phagocytosis of large particles. Since we observed a decrease in therapeutic efficacy when mice were treated with PBS-liposomes, we were concerned that the ingestion of liposome particles may have decreased the functional response to TLR9 stimulation. Therefore, we used an in vitro system to evaluate macrophagemediated anti-tumor activity.
aCD40 primed macrophages can act as effector cells against numerous mouse and human tumors [7, [40] [41] [42] . aCD40 activated human macrophages mediate anti-tumor responses to human pancreatic cancer [43] . Few reports have evaluated CD40 and/or CpG activation of macrophages for increasing antibody responses. The data presented here demonstrate at least a partial role for aCD40 ? CPG primed macrophages in response to tumortargeted hu14.18K322A.
Using a co-culture system, we found that enriched aCD40 ? CpG primed macrophages could inhibit tumor cell proliferation in an antibody-dependent manner (Fig. 6 ). These in vitro data suggest that macrophages are involved in the anti-tumor response. Clinical data from our laboratory have recently suggested that myeloid cells may play a role in the therapeutic effect of mAb in neuroblastoma patients [20, 44, 45] . In a small phase II study of hu14.18-IL2 immunocytokine, we observed a clear association between the expression of a high affinity Fc receptor on myeloid cells (CD32) and clinical response [20, 45] . Furthermore, we participated in recently demonstrating that aGD2 mAb ch14.18, when combined with GMCSF and interleukin-2 (IL2) is better than the standard of care for high-risk neuroblastoma patients [44] . Although not compared directly, ch14.18 ? GMCSF ? IL2 appeared to have a bigger impact on survival than ch14.18-IL2 mAb alone, without GMCSF [44] [45] [46] . While more data are needed, these two studies may suggest an important role for myeloid cells in the response to aGD2 mAbs in patients with neuroblastoma.
